Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival

14 Aug 2019

Abstract excerpt

BACKGROUND: -methyl guanine DNA methyltransferase (MGMT) that is often characterised by unmethylated promoter. Here, we investigated pre-treatment of glioblastoma (GBM) cells with the 26S-proteasome inhibitor bortezomib (BTZ) as a strategy to interfere with MGMT expression and thus sensitise them to TMZ. METHODS: Cell lines and patient GBM-derived cells were examined in vitro, and the latter also implanted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Glioma Diagnosis and Treatment
Share to Hedgehog Signaling Pathway Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31413318
DOI: 10.1038/s41416-019-0551-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survivalPMID 31413318Read ↗

Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized MedicineSemantic proximity Read ↗

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expressionSemantic proximity Read ↗

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expressionSemantic proximity Read ↗

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1Semantic proximity Read ↗

Prognostic value of O‐6‐methylguanine–DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysisSemantic proximity Read ↗

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapySemantic proximity Read ↗

Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in GlioblastomaSemantic proximity Read ↗

MGMT inhibition regulates radioresponse in GBM, GSC, and melanomaSemantic proximity Read ↗

Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell CultureSemantic proximity Read ↗

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft modelsSemantic proximity Read ↗

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomideSemantic proximity Read ↗

Clinical Trial Substantiates the Predictive Value of <b> <i>O-6-Methylguanine-DNA Methyltransferase</i> </b> Promoter Methylation in Glioblastoma Patients Treated with TemozolomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.